Clinical Trial Detail

NCT ID NCT01808573
Title A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Puma Biotechnology, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Lapatinib

Capecitabine + Neratinib

Age Groups: senior adult

Additional content available in CKB BOOST